Skip to main content

Advertisement

SpringerLink
Log in

Significantly high expression of platelet-derived growth factor (PDGF) in benign nodules of the thyroid: relevance in the development of goitre recurrence?

  • Original Article
  • Published:
Langenbeck's Archives of Surgery Aims and scope Submit manuscript

Abstract

Purpose

Platelet-derived growth factor (PDGF) is a critical regulator of cell proliferation and influences the development of tumors. The role of PDGF in benign thyroid diseases is presently not well-determined. The purpose is to evaluate PDGF isoforms and receptors in primary culture of thyrocytes isolated from human thyroid tissue.

Methods

Forty patients with uninodular (n = 11), multinodular (n = 15) and recurrent goitre (n = 14) were investigated. Nodular and corresponding paranodular thyroid tissues were characterized. RNA and protein were extracted from primary thyrocyte monoculture. RT-PCR, western blot and ELISA were performed to evaluate PDGF isoforms AA, BB, CC, DD and PDGF receptors α and β.

Results

Significantly higher mRNA expression of PDGF-AA, -BB, -CC and PDGFR molecules α and β was measured by RT-PCR in thyrocytes from uninodular and recurrent nodular tissue compared with corresponding paranodular tissue. Elevated PDGF protein and PDGFR-α and -β were confirmed by western blot. Likewise, higher secretion of PDGF-AA and -BB was detected in the supernatant of thyrocyte culture from all nodular tissue compared with paranodular tissue. Interestingly, comparison of nodular and corresponding paranodular tissues in multinodular goitre did not show significant difference of expression levels of PDGF isoforms or receptors.

Conclusion

These findings suggest that the overexpression of PDGF isoforms and receptors may play a crucial role in the development of thyroid nodules and recurrent goitre.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Ross R, Glosmet J, Kariya B, Laurence H (1974) A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro. Proc Natl Acad Sci 7:1207–1210

    Article  Google Scholar 

  2. Fredriksson L, Li H, Eriksson U (2004) The PDGF family: four gene products form five dimeric isoforms. Cytokine Growth Factor Rev 15:197–204

    Article  PubMed  CAS  Google Scholar 

  3. Li X, Ponten A, Aase K, Karlsson L, Abramsson A, Uutela M, Backstrom G, Hellstrom M, Bostrom H, Li H, Soriano P, Betsholtz C, Heldin CH, Alitalo K, Ostman A, Eriksson U (2000) PDGF-C is a new protease-activated ligand for the PDGF-receptor. Nat Cell Biol 2:302–309

    Article  PubMed  CAS  Google Scholar 

  4. Bergsten E, Uutela M, Li X, Pietras K, Ostman A, Heldin CH, Alitalo K, Eriksson U (2001) PDGF-D is a specific, protease-activated ligand for the PDGF beta-receptor. Nat Cell Biol 3:512–516

    Article  PubMed  CAS  Google Scholar 

  5. LaRochelle WJ, Jeffers M, McDonald WF (2001) PDGF-D, a new protease-activated growth factor. Nat Cell Biol 3:517–521

    Article  PubMed  CAS  Google Scholar 

  6. Heldin C-H, Wasteson A, Westermark B (1985) Platelet-derived growth factor. Mol Cell Endocrinol 39:169–187

    Article  PubMed  CAS  Google Scholar 

  7. Deuel TF, Huang JS (1984) Platelet-derived growth factor. Structure, function, and roles in normal and transformed cells. J Clin Invest 74:669–676

    Article  PubMed  CAS  Google Scholar 

  8. Li M, Jendrossek V, Belka C (1995) The role of PDGF in radiation oncology. Radiat Oncol 2:5

    Article  CAS  Google Scholar 

  9. Westermark B (1995) Platelet-derived growth factor. A growth factor of great physiopathological importance. Lakartidningen 7(92(23)):2397–2401

    Google Scholar 

  10. Chen K-T, Lin J-D, Liou M-J, Wenig H-F, Chang CA, Chan EC (2006) An aberrant autocrine activation of the platelet-derived growth factor α-receptor in follicular and papillary thyroid carcinoma cell lines. Cancer Lett 231:192–205

    Article  PubMed  CAS  Google Scholar 

  11. Heldin NE, Gustavsson B, Claesson-Welsh L, Hammacher A, Mark J, Heldin CH, Westermark B (1988) Aberrant expression of receptors for platelet-derived growth factor in an anaplastic thyroid carcinoma cell line. Proc Natl Acad Sci 85(23):9302–9306

    Article  PubMed  CAS  Google Scholar 

  12. Yano Y, Uematsu N, Yashiro T, Hara H, Ueno E, Miwa M, Tsujimoto G, Aiyoshi Y, Uchida K (2004) Gene expression profiling identifies platelet-derived growth factor as a diagnostic molecular marker for papillary thyroid carcinoma. Clin Cancer Res 10:2035–2043

    Article  PubMed  CAS  Google Scholar 

  13. Derwahl M (1998) Von der diffusen Struma zur Knotenstruma. Internist 39:577–583

    Article  PubMed  CAS  Google Scholar 

  14. Westermark K, Lundqvist M, Wallin G, Dahlman T, Hacker GW, Heldin NE, Grimelius L (1996) EGF-receptors in human normal and pathological thyroid tissue. Histopathology 28(3):221–227

    Article  PubMed  CAS  Google Scholar 

  15. Heldin C-H, Westermark B (1999) Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79:1283–1316

    PubMed  CAS  Google Scholar 

  16. Reis RM, Martins A, Ribeiro SA, Basto D, Longatto-Filho A, Schmitt FC, Lopes JM (2005) Molecular characterization of PDGFR-alpha/PDGF-A and c-KIT/SCF in gliosarcomas. Cell Oncol 27:319–326

    PubMed  CAS  Google Scholar 

  17. Anan K, Morisaki T, Katano M, Ikubo A, Kitsuki H, Uchiyama A, Kuroki S, Tanaka M, Torisu M (1996) Vascular endothelial growth factor and platelet-derived growth factor are potential angiogenic and metastatic factors in human breast cancer. Surgery 119(3):333–339

    Article  PubMed  CAS  Google Scholar 

  18. Sundberg C, Branting M, Gerdin B, Rubin K (1997) Tumor cell and connective tissue cell interactions in human colorectal adenocarcinoma. Transfer of platelet-derived growth factor-AB/BB to stromal cells. Am J Pathol 151(2):479–492

    PubMed  CAS  Google Scholar 

  19. Uhrbom L, Hesselager G, Ostman A, Nistér M, Westermark B (2000) Dependence of autocrine growth factor stimulation in platelet-derived growth factor-B-induced mouse brain tumor cells. Int J Cancer 85(3):398–406

    Article  PubMed  CAS  Google Scholar 

  20. Torino F, Corsello SM, Longo R, Barnabei A, Gasparini G (2009) Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol 6(4):219–228

    Article  PubMed  CAS  Google Scholar 

  21. Mannavola D, Coco P, Vannucchi G, Bertuelli R, Carletto M, Casali PG, Beck-Peccoz P, Fugazzola L (2007) A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab 92(9):3531–3534

    Article  PubMed  CAS  Google Scholar 

  22. Sun J, Wang DA, Jain RK, Carie A, Paquette S, Ennis E, Blaskovich MA, Baldini L, Coppola D, Hamilton AD, Sebti SM (2005) Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors. Oncogene 24(29):4701–4709

    Article  PubMed  CAS  Google Scholar 

  23. Vaiman M, Nagibin A, Hagag P, Buyankin A, Olevson J, Shlamkovich N (2008) Subtotal and near total versus total thyroidectomy for the management of multinodular goiter. World J Surg 32:1546–1551

    Article  PubMed  Google Scholar 

  24. Snook KL, Stalberg PLH, Sidhu SB, Sywak MS, Edhouse P, Delbridge L (2007) Recurrence after total thyroidectomy for benign multinodular goiter. World J Surg 31:593–598

    Article  PubMed  Google Scholar 

  25. Moalem J, Suh I, Duh Q-Y (2008) Treatment and prevention of recurrence of multinodular goiter: an evidence-based review of the literature. World J Surg 32:1301–1312

    Article  PubMed  Google Scholar 

  26. Gibelin H, Sierra M, Mothes D, Ingrand P, Levillain P, Jones C, Hadjadj S, Torremocha F, Marechaud R, Barbier J, Kraimps J-L (2004) Risk factors for recurrent nodular goiter after thyroidectomy for benign diseases: case-control study of 244 patients. World J Surg 28:1079–1082

    Article  PubMed  Google Scholar 

  27. Basili G, Biagini C, Manetti A, Martini F, Biliotti G (2004) Risk of recurrence following partial thyroidectomy for benign lesions. Report of 58 patients 15–25 years after surgery. Minerva Chir 58:321–329

    Google Scholar 

  28. Sato K, Miyakawa M, Onoda N, Demura H, Yamashita T, Miura M, Kasajima T, Yamazaki K, Obara T (1997) Increased concentration of vascular endothelial growth factor/vascular permeability factor in cyst fluid of enlarging and recurrent thyroid nodules. J Clin Endocrinol Metab 82:1968–1973

    Article  PubMed  CAS  Google Scholar 

  29. Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23(5):1011–1027

    Article  PubMed  CAS  Google Scholar 

  30. Wang D, Huang HJ, Kazlauskas A, Cavenee WK (1999) Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase. Cancer Res 59(7):1464–1472

    PubMed  CAS  Google Scholar 

  31. Lederle W, Stark H-J, Skobe M, Fusenig NE, Mueller MM (2006) Platelet-derived growth factor-BB controls epithelial tumor phenotype by differential growth factor regulation in stromal cells. Am J Pathol 169(5):1767–1783

    Article  PubMed  CAS  Google Scholar 

  32. Kano MR, Morishita Y, Iwata C, Iwasaka S, Watabe T, Ouchi Y, Miyazono K, Miyazawa K (2005) VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B-PDGFRbeta signaling. J Cell Sci 118(16):3759–3768

    Article  PubMed  CAS  Google Scholar 

  33. Ríos Zambudio A, Rodríguez González JM, Galindo Fernández PJ, Montoya Tabares MJ, Canteras Jordana M, Parilla Paricio P (2005) Clinical recurrence of multinodular goitre after surgery. A multivariate study on the risk factors. Rev Clín Esp 205(1):9–13

    Article  PubMed  Google Scholar 

  34. Phitayakorn R, Super DM, McHenry CR (2006) An investigation of epidemiologic factors associated with large nodular goiter. J Surg Res 133(1):16–21

    Article  PubMed  CAS  Google Scholar 

  35. Ríos A, Rodríguez JM, Canteras M, Galindo PJ, Balsalobre MD, Parrilla P (2004) Risk factors for malignancy in multinodular goiters. Eur J Surg Oncol 30(1):58–62

    Article  PubMed  Google Scholar 

Download references

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Department of General Surgery, Johann-Wolfgang Goethe University, Universitätsklinikum Frankfurt am Main, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany

    Patrizia Malkomes, Elsie Oppermann, Wolf-Otto Bechstein & Katharina Holzer

Authors
  1. Patrizia Malkomes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elsie Oppermann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wolf-Otto Bechstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Katharina Holzer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Patrizia Malkomes or Katharina Holzer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Malkomes, P., Oppermann, E., Bechstein, WO. et al. Significantly high expression of platelet-derived growth factor (PDGF) in benign nodules of the thyroid: relevance in the development of goitre recurrence?. Langenbecks Arch Surg 396, 1165–1172 (2011). https://doi.org/10.1007/s00423-011-0799-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00423-011-0799-2

Keywords

Search

Navigation